Epidemiology Data Slicer – Chronic Heart Failure
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of…
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Chronic Heart Failure disease patient populations covering 171 countries…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of…
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s…
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s…
Treatment of heart failure with reduced ejection fraction (HFrEF) is well established with a wealth of evidence from clinical trials that supports the use of all standard-of-care therapies for CHF…
DRG Epidemiology's coverage of heart failure (HF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed event rates of AHF…
PAH is a rare, life-threatening disorder marked by considerable morbidity and mortality. Despite the availability of a wide array of drugs for PAH, substantial unmet need remains for more-…
Drug treatment of chronic heart failure (CHF) with reduced ejection fraction (HFrEF) is well established with a wealth of supporting evidence from clinical trials. ACE inhibitors or ARBs, beta…
First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, and an oral diuretic. The addition of a second- or third…